These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34142274)

  • 21. Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa.
    Laurent C; Yaya I; Cuer B; Sagaon-Teyssier L; Mensah E; Dah TTE; Coulibaly A; Kouamé MJ; Peytavin G; Serrano L; Eubanks A; Traoré I; Diallo F; Riegel L; Rojas Castro D; Dagnra CA; Anoma C; Vuylsteke B; Dembélé Keita B; Spire B;
    Clin Infect Dis; 2023 Aug; 77(4):606-614. PubMed ID: 37052469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salient Constructs for the Development of Shared Decision-Making Tools for HIV Pre-Exposure Prophylaxis Uptake and Regimen Choice: Behaviors, Behavioral Skills, and Beliefs.
    Meyers K; Wu Y; Shin KY; Hou J; Hu Q; Duan J; Li Y; He X
    AIDS Patient Care STDS; 2021 Jun; 35(6):195-203. PubMed ID: 34037427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brief Report: Refusal of Daily Oral PrEP: Implementation Considerations and Reported Likelihood of Using Various HIV Prophylaxis Products in a Diverse Sample of MSM.
    Mansergh G; Kota KK; Carnes N; Gelaude D
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):212-216. PubMed ID: 36442153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Who prefers what? Correlates of preferences for next-generation HIV prevention products among a national U.S. sample of young men who have sex with men.
    Biello KB; Valente PK; da Silva DT; Lin W; Drab R; Hightow-Weidman L; Mayer KH; Bauermeister JA;
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26096. PubMed ID: 37439061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Awareness of, interest in, and willingness to pay for HIV pre-exposure prophylaxis among Canadian gay, bisexual, and other men who have sex with men.
    Morgan J; Ferlatte O; Salway T; Wilton J; Hull M
    Can J Public Health; 2018 Dec; 109(5-6):791-799. PubMed ID: 29981103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient and Physician Preferences Regarding Long-Acting Pre-Exposure Prophylaxis and Antiretroviral Therapy: A Mixed-Methods Study in Southern California, USA.
    Yeager S; Montoya JL; Burke L; Chow K; Moore DJ; Morris S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):856-862. PubMed ID: 35972754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.
    Beymer MR; Holloway IW; Pulsipher C; Landovitz RJ
    Curr HIV/AIDS Rep; 2019 Aug; 16(4):349-358. PubMed ID: 31222499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011-2017: Implications for Further Implementation from a Diffusion of Innovations Perspective.
    Holt M; Lea T; Bear B; Halliday D; Ellard J; Murphy D; Kolstee J; de Wit J
    AIDS Behav; 2019 Jul; 23(7):1939-1950. PubMed ID: 30539496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "How PrEPared are you?": Knowledge of and attitudes toward PrEP among overseas-born and newly arrived gay, bisexual, and other men who have sex with men in Australia.
    Sudarto B; Chow EPF; Medland N; Fairley CK; Wright EJ; Armishaw J; Price B; Phillips TR; Ong JJ
    Front Public Health; 2022; 10():946771. PubMed ID: 36062118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence.
    John SA; Rendina HJ; Grov C; Parsons JT
    PLoS One; 2017; 12(12):e0189794. PubMed ID: 29281688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Global Impact of Diversifying PrEP Options: Results of an International Discrete Choice Experiment of Existing and Potential PrEP Strategies with Gay and Bisexual Men and Physicians.
    Tagliaferri Rael C; Giguere R; Bryndza Tfaily E; Sutton S; Horn E; Schieffer RJ; Hendrix C; D'Aquila RT; Hope TJ
    AIDS Res Hum Retroviruses; 2024 Oct; 40(10):591-605. PubMed ID: 38753738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.
    Lorenzetti L; Dinh N; van der Straten A; Fonner V; Ridgeway K; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26107. PubMed ID: 37439057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L; Magno L; Zucchi EM; da Silva LAV; Ferraz D; Grangeiro A; Castellanos M; Brasil SA; Dourado I
    BMC Public Health; 2022 Sep; 22(1):1728. PubMed ID: 36096758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men.
    Biello KB; Hosek S; Drucker MT; Belzer M; Mimiaga MJ; Marrow E; Coffey-Esquivel J; Brothers J; Mayer KH
    Arch Sex Behav; 2018 Oct; 47(7):2101-2107. PubMed ID: 28929260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perceived Versus Actual Costs of HIV Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States.
    Dawit R; Predmore Z; Raifman J; Chan PA; Dean LT
    AIDS Patient Care STDS; 2024 Oct; 38(10):468-476. PubMed ID: 39293419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of HIV Pre-exposure Prophylaxis (PrEP) Associated With Lower HIV Anxiety Among Gay and Bisexual Men in Australia Who Are at High Risk of HIV Infection: Results From the Flux Study.
    Keen P; Hammoud MA; Bourne A; Bavinton BR; Holt M; Vaccher S; Haire B; Saxton P; Jin F; Maher L; Grulich AE; Prestage G
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):119-125. PubMed ID: 31935203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorrect Knowledge of Event-Driven PrEP "2-1-1" Dosing Regimen Among PrEP-Experienced Gay and Bisexual Men in Australia.
    Chan C; Vaccher S; Fraser D; Grulich AE; Holt M; Zablotska-Manos I; Prestage GP; Bavinton BR
    J Acquir Immune Defic Syndr; 2022 Jun; 90(2):132-139. PubMed ID: 35135976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.